%0 Journal Article
%A Rojas Lozano, Pilar
%A Hoz Montañana, María Rosa de
%A Cadena Santoyo, Manuel
%A García Martín, Elena Salobrar
%A Fernández Albarral, José Antonio
%A López Cuenca, Inés
%A Elvira Hurtado, Lorena
%A Urcelay Segura, José Luis
%A Salazar Corral, Juan José
%A Ramirez Sebastian, Jose Manuel
%A Ramírez Sebastián, Ana Isabel
%T Neuro-Ophthalmological Findings in Friedreich’s Ataxia
%D 2021
%@ 2075-4426
%U https://hdl.handle.net/20.500.14352/4438
%X Friedreich ataxia (FRDA) is a progressive neurodegenerative disease caused by a severe autosomal recessive genetic disorder of the central nervous (CNS) and peripheral nervous system (PNS), affecting children and young adults. Its onset is before 25 years of age, with mean ages of onset and death between 11 and 38 years, respectively. The incidence is 1 in 30,000–50,000 persons. It is caused, in 97% of cases, by a homozygous guanine-adenine-adenine (GAA) trinucleotide mutation in the first intron of the frataxin (FXN) gene on chromosome 9 (9q13–q1.1). The mutation of this gene causes a deficiency of frataxin, which induces an altered inflow of iron into the mitochondria, increasing the nervous system’s vulnerability to oxidative stress. The main clinical signs include spinocerebellar ataxia with sensory loss and disappearance of deep tendon reflexes, cerebellar dysarthria, cardiomyopathy, and scoliosis. Diabetes, hearing loss, and pes cavus may also occur, and although most patients with FRDA do not present with symptomatic visual impairment, 73% present with clinical neuro-ophthalmological alterations such as optic atrophy and altered eye movement, among others. This review provides a brief overview of the main aspects of FRDA and then focuses on the ocular involvement of this pathology and the possible use of retinal biomarkers.
%~